Skip to main content

BGI, Leiden to Use FlexGen Target Enrichment in Dutch Genome Project

Premium

FlexGen of the Netherlands said last week that China's BGI and Leiden University Medical Center will use its target enrichment technology to validate variants for the Genome of the Netherlands, or GoNL, project.

The researchers will use the platform to validate a set of variants found in trio samples from the GoNL project. Launched in 2010, the project aims to sequence the genomes of about 250 Dutch parent-child trios. The sequencing is performed at BGI's Hong Kong facility.

FlexGen, located in the Leiden Bio Science Park, was founded in 2004 as a spinoff from Leiden University Medical Center and Dutch Space. The company offers FleXelect custom target enrichment kits.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.